In This Section

Home / Learn / Oncology Pharmacy

Oncology Pharmacy Education Network

Oncology pharmacy services standards and guidelines are addressed by several regulatory agencies and professional organizations. Standards and guidelines sometimes apply to specific settings of care (as an example, The Joint Commission for hospitals), but the principles pertaining to quality, safety, and effectiveness of cancer care are the concern of Oncology Pharmacy Services in all sites of care. 

With the increasing complexity of cancer care, new indications and new drug approvals, emerging biosimilars in oncology, recent advances in immunotherapy, the high cost cancer treatment, and the ever-evolving regulatory and reimbursement landscape, the challenges for Oncology Pharmacy Services are ongoing.

ACCC provides education, resources, and networking opportunities to help cancer programs navigate care coordination issues specific to pharmacy such as reimbursement, distribution, inventory management, communication and training through the Oncology Pharmacy Education Network.


From Oncology Issues

  • Implementation of Drug Vial Optimization to Reduce Drug Waste
    Lindsey B. Amerine, PharmD, MS, BCPS; Scott W. Savage, PharmD, MS; Erinn C. Rowe, PharmD, MS; Rowell Daniels, PharmD, MS, FASHP; John M. Valgus, PharmD, MHA, BCOP; Richard Redding, BA, CPHT; and Stephen F. Eckel, PharmD, MHA, BCPS
    In the Department of Pharmacy at the University of North Carolina North Carolina Cancer Hospital, discarding partial drug vials was a significant source of waste. With their Innovator Award–winning drug vial optimization program, the program maximized the lifespan of drugs within single-dose vials and realized an annual cost savings of more than $40 million.
  • Immuno-Oncology: Breaking Barriers, Exploring Solutions, Improving Patient Care
    The ACCC Immuno-Oncology Institute developed a multidisciplinary curriculum workshop bringing together faculty experienced in delivery of immunotherapy with cancer program staff in the earlier stages of IO integration. Over the past two years, these IO Visiting Experts Programs were hosted by ACCC Cancer Program Members nation-wide.
  •  CRISPR-Directed Gene Editing in a Community Cancer Center
    Eric B. Kmiec, PhD
    CRISPR, a gene editing tool, has entered the scientific arena and public discourse at an astounding speed. Eric B. Kmiec, PhD, director of the Gene Editing Institute at the Helen F. Graham Cancer Center & Research Institute, discusses the emergence of gene editing, how it can be utilized as a tool in the battle against cancer, and the challenges facing its transition from bench to bedside.
  •  Supportive Oncodermatology
    Stephanie Kao, BA, and Adam Friedman, MD
    Dermatologic adverse events can have a profound impact on the physical, emotional, financial, and psychosocial health of cancer patients. Discover how the emerging collaborative subspecialty of supportive oncodermatology aims to address cancer-related dermatologic events.
  •  Tools

Additional Resources


Patient-Centered Scheduling: Costs & Benefits of Extending Practice Hours

This special report from ACCC examines the pros and cons of extended infusion suite hours. Included is tool to help practices and programs assess the feasibility of extending hours of care.

Oral Chemotherapy

Dispensing Pharmacy Patient Education Tool

Physician dispensing is governed by state law and regulated by State Boards of Pharmacy. While some states do not allow physician dispensing, most of the states that allow it require dispensing physicians to alert their patients about other options to fill their prescription(s). In response to this need, ACCC has developed this patient education tool that can be used across care settings.

News Coverage

At the 2018 ASCO Annual Meeting, Oncology Business Review interviewed ACCC member Ivo Abraham, PhD, RN, for an update on biosimilars in oncology. Dr. Abraham is Professor of Pharmacy and Medicine at the University of Arizona in Tucson, Arizona, where he is also affiliated with the Center for Health Outcomes and PharmacoEconomic Research, the Arizona Cancer Center, and the Center for Applied Genomics and Genetic Medicine. Dr. Abraham is a member of the ACCC Immuno-Oncology Institute Executive Committee.

Dr. Abraham shares his perspective on hurdles to adoption of biosimilars in oncology:

Oncology Drug Database

Access ACCC's comprehensive resource for coding, billing, and reimbursement for oncology drugs.
Access the Database

ACCCBuzz Blog Posts

Oral Chemotherapy education